The role of immunosuppression in recurrence of hepatitis C

Liver Transplantation

Volumn 9, Issue 11, 2003, Pages

  Lake, John R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ARTICLE; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; NONHUMAN; PATHOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; RECURRENT INFECTION; VIRUS PATHOGENESIS;

EID: 0242624528     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50264     Document Type: Article

References (20)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
2. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412-418.
3. Papatheodoridis GV, Barron SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viramenia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999;45:427-434.
4. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl):S107-S114.
5. Gane EJ, Naoumov NV, Qian KP, Mondelli MN, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
6. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
7. Sreckumar R, Gonzales-Koch A, Maor-Kendler Y, Batts Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130.
8. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
9. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998;66: 493-499.
10. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transpl 2001;7:693-697.
11. Kneteman NM. Steroid-free immunosuppression: Balancing efficacy and toxicity. Liver Transpl 2001;7:698-700.
12. Brillanti S, Vivarelli M, DeRuvo N, Aden AA, Camaggi V, D'Errico AD, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
13. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-450.
14. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:40-46.
15. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, et al. Lower incidences of early hepatitis C RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: A high-dose benefit [abstract]. Liver Transpl 2002;8:C52A.
16. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-1070.
17. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basilixamab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-131.
18. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abey-wickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
19. Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999;31:1113-1114.
20. Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003;9:57-61.